Comparing efficacy of fibrates and statins in isolated and combined hypertriglyceridemia and various types of oxidative metabolism

Aim. To compare efficacy of simvastatin, a II generation statin, and ciprofibrate, a III generation fibrate, in various types of hyperlipidemia (HLP) and fibrate pharmacokinetic variants. Material and methods. The authors examined 156 males with primary HLP, aged 41-59. Inclusion criteria were: init...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	G. S. Mal’ [verfasserIn]

Format:	E-Artikel
Sprache:	Russisch

Erschienen:	2005

Schlagwörter:	гипертриглицеридемия ципрофибрат фенотип окисления симвастатин

Übergeordnetes Werk:	In: Кардиоваскулярная терапия и профилактика - «SILICEA-POLIGRAF» LLC, 2019, 4(2005), 3, ч.II, Seite 69-74
Übergeordnetes Werk:	volume:4 ; year:2005 ; number:3, ч.II ; pages:69-74

Links:	Link aufrufen Link aufrufen Journal toc Journal toc

Katalog-ID:	DOAJ02410261X

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ02410261X
003	DE-627
005	20230410104803.0
007	cr uuu---uuuuu
008	230226s2005 xx \|\|\|\|\|o 00\| \|\|rus c
035			\|a (DE-627)DOAJ02410261X
035			\|a (DE-599)DOAJ22fc39d529bb43c5be5d83422fbc8567
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a rus
050		0	\|a RC666-701
100	0		\|a G. S. Mal’ \|e verfasserin \|4 aut
245	1	0	\|a Comparing efficacy of fibrates and statins in isolated and combined hypertriglyceridemia and various types of oxidative metabolism
264		1	\|c 2005
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Aim. To compare efficacy of simvastatin, a II generation statin, and ciprofibrate, a III generation fibrate, in various types of hyperlipidemia (HLP) and fibrate pharmacokinetic variants. Material and methods. The authors examined 156 males with primary HLP, aged 41-59. Inclusion criteria were: initial cholesterol (CH) >190 mg/dl; triglycerides (TG) >150 mg/dl; high-density lipoprotein CH >35 mg/dl. Clinical, biochemical, pharmacokinetic, and statistical methods were used. Results. Analysis of lipid-transport system in patients with isolated hypertriglyceridemia (HTG) during 8-week ciprofibrate therapy demonstrated decreases in TG (by 39.2%; pIII-V<0.05), and atherogenicity index, AI (by 28.6%; pIII-V<0.05). In patients with HTG and hypercholesterolemia (HCH), CH level was significantly reduced (by 13.1%; pIII-V<0.05), mostly due to 33.1% decrease in low-density lipoprotein CH (pIII-V<0.001). Analysis of the association between ciprofibrate-induced TG decrease and oxidative parameters demonstrated greater numbers of the patients with inadequate hypotriglyceridemic effect among “fast” oxidative metabolisers than among “slow” ones. Among individuals with “fast” oxidation phenotype, ciprofibrate therapy had a moderate hypotriglyceridemic effect in 67% of subjects (p<0.05). Conclusion. In combined HTG and HCH, substantial hypotriglyceridemic activity of ciprofibrate was observed among patients with “slow” oxidation phenotype: TG concentration decreased by 35% (р<0.001). In “fast” oxidation phenotype group, TG level was reduced by 30% (р<0.05). Participants with both isolated and combined HTG demonstrated a substantial hypolipidemic effect of ciprofibrate in “slow” oxidation phenotype.
650		4	\|a гипертриглицеридемия
650		4	\|a ципрофибрат
650		4	\|a фенотип окисления
650		4	\|a симвастатин
653		0	\|a Diseases of the circulatory (Cardiovascular) system
773	0	8	\|i In \|t Кардиоваскулярная терапия и профилактика \|d «SILICEA-POLIGRAF» LLC, 2019 \|g 4(2005), 3, ч.II, Seite 69-74 \|w (DE-627)1725534363 \|x 26190125 \|7 nnns
773	1	8	\|g volume:4 \|g year:2005 \|g number:3, ч.II \|g pages:69-74
856	4	0	\|u https://doaj.org/article/22fc39d529bb43c5be5d83422fbc8567 \|z kostenfrei
856	4	0	\|u https://cardiovascular.elpub.ru/jour/article/view/954 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1728-8800 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2619-0125 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 4 \|j 2005 \|e 3, ч.II \|h 69-74

Indexfelder

author_variant	g s m gsm
matchkey_str	article:26190125:2005----::oprnefccofbaeadttniioaeadobndyetilcrdmanvr
hierarchy_sort_str	2005
callnumber-subject-code	RC
publishDate	2005
allfields	(DE-627)DOAJ02410261X (DE-599)DOAJ22fc39d529bb43c5be5d83422fbc8567 DE-627 ger DE-627 rakwb rus RC666-701 G. S. Mal’ verfasserin aut Comparing efficacy of fibrates and statins in isolated and combined hypertriglyceridemia and various types of oxidative metabolism 2005 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim. To compare efficacy of simvastatin, a II generation statin, and ciprofibrate, a III generation fibrate, in various types of hyperlipidemia (HLP) and fibrate pharmacokinetic variants. Material and methods. The authors examined 156 males with primary HLP, aged 41-59. Inclusion criteria were: initial cholesterol (CH) >190 mg/dl; triglycerides (TG) >150 mg/dl; high-density lipoprotein CH >35 mg/dl. Clinical, biochemical, pharmacokinetic, and statistical methods were used. Results. Analysis of lipid-transport system in patients with isolated hypertriglyceridemia (HTG) during 8-week ciprofibrate therapy demonstrated decreases in TG (by 39.2%; pIII-V<0.05), and atherogenicity index, AI (by 28.6%; pIII-V<0.05). In patients with HTG and hypercholesterolemia (HCH), CH level was significantly reduced (by 13.1%; pIII-V<0.05), mostly due to 33.1% decrease in low-density lipoprotein CH (pIII-V<0.001). Analysis of the association between ciprofibrate-induced TG decrease and oxidative parameters demonstrated greater numbers of the patients with inadequate hypotriglyceridemic effect among “fast” oxidative metabolisers than among “slow” ones. Among individuals with “fast” oxidation phenotype, ciprofibrate therapy had a moderate hypotriglyceridemic effect in 67% of subjects (p<0.05). Conclusion. In combined HTG and HCH, substantial hypotriglyceridemic activity of ciprofibrate was observed among patients with “slow” oxidation phenotype: TG concentration decreased by 35% (р<0.001). In “fast” oxidation phenotype group, TG level was reduced by 30% (р<0.05). Participants with both isolated and combined HTG demonstrated a substantial hypolipidemic effect of ciprofibrate in “slow” oxidation phenotype. гипертриглицеридемия ципрофибрат фенотип окисления симвастатин Diseases of the circulatory (Cardiovascular) system In Кардиоваскулярная терапия и профилактика «SILICEA-POLIGRAF» LLC, 2019 4(2005), 3, ч.II, Seite 69-74 (DE-627)1725534363 26190125 nnns volume:4 year:2005 number:3, ч.II pages:69-74 https://doaj.org/article/22fc39d529bb43c5be5d83422fbc8567 kostenfrei https://cardiovascular.elpub.ru/jour/article/view/954 kostenfrei https://doaj.org/toc/1728-8800 Journal toc kostenfrei https://doaj.org/toc/2619-0125 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2005 3, ч.II 69-74
spelling	(DE-627)DOAJ02410261X (DE-599)DOAJ22fc39d529bb43c5be5d83422fbc8567 DE-627 ger DE-627 rakwb rus RC666-701 G. S. Mal’ verfasserin aut Comparing efficacy of fibrates and statins in isolated and combined hypertriglyceridemia and various types of oxidative metabolism 2005 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim. To compare efficacy of simvastatin, a II generation statin, and ciprofibrate, a III generation fibrate, in various types of hyperlipidemia (HLP) and fibrate pharmacokinetic variants. Material and methods. The authors examined 156 males with primary HLP, aged 41-59. Inclusion criteria were: initial cholesterol (CH) >190 mg/dl; triglycerides (TG) >150 mg/dl; high-density lipoprotein CH >35 mg/dl. Clinical, biochemical, pharmacokinetic, and statistical methods were used. Results. Analysis of lipid-transport system in patients with isolated hypertriglyceridemia (HTG) during 8-week ciprofibrate therapy demonstrated decreases in TG (by 39.2%; pIII-V<0.05), and atherogenicity index, AI (by 28.6%; pIII-V<0.05). In patients with HTG and hypercholesterolemia (HCH), CH level was significantly reduced (by 13.1%; pIII-V<0.05), mostly due to 33.1% decrease in low-density lipoprotein CH (pIII-V<0.001). Analysis of the association between ciprofibrate-induced TG decrease and oxidative parameters demonstrated greater numbers of the patients with inadequate hypotriglyceridemic effect among “fast” oxidative metabolisers than among “slow” ones. Among individuals with “fast” oxidation phenotype, ciprofibrate therapy had a moderate hypotriglyceridemic effect in 67% of subjects (p<0.05). Conclusion. In combined HTG and HCH, substantial hypotriglyceridemic activity of ciprofibrate was observed among patients with “slow” oxidation phenotype: TG concentration decreased by 35% (р<0.001). In “fast” oxidation phenotype group, TG level was reduced by 30% (р<0.05). Participants with both isolated and combined HTG demonstrated a substantial hypolipidemic effect of ciprofibrate in “slow” oxidation phenotype. гипертриглицеридемия ципрофибрат фенотип окисления симвастатин Diseases of the circulatory (Cardiovascular) system In Кардиоваскулярная терапия и профилактика «SILICEA-POLIGRAF» LLC, 2019 4(2005), 3, ч.II, Seite 69-74 (DE-627)1725534363 26190125 nnns volume:4 year:2005 number:3, ч.II pages:69-74 https://doaj.org/article/22fc39d529bb43c5be5d83422fbc8567 kostenfrei https://cardiovascular.elpub.ru/jour/article/view/954 kostenfrei https://doaj.org/toc/1728-8800 Journal toc kostenfrei https://doaj.org/toc/2619-0125 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2005 3, ч.II 69-74
allfields_unstemmed	(DE-627)DOAJ02410261X (DE-599)DOAJ22fc39d529bb43c5be5d83422fbc8567 DE-627 ger DE-627 rakwb rus RC666-701 G. S. Mal’ verfasserin aut Comparing efficacy of fibrates and statins in isolated and combined hypertriglyceridemia and various types of oxidative metabolism 2005 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim. To compare efficacy of simvastatin, a II generation statin, and ciprofibrate, a III generation fibrate, in various types of hyperlipidemia (HLP) and fibrate pharmacokinetic variants. Material and methods. The authors examined 156 males with primary HLP, aged 41-59. Inclusion criteria were: initial cholesterol (CH) >190 mg/dl; triglycerides (TG) >150 mg/dl; high-density lipoprotein CH >35 mg/dl. Clinical, biochemical, pharmacokinetic, and statistical methods were used. Results. Analysis of lipid-transport system in patients with isolated hypertriglyceridemia (HTG) during 8-week ciprofibrate therapy demonstrated decreases in TG (by 39.2%; pIII-V<0.05), and atherogenicity index, AI (by 28.6%; pIII-V<0.05). In patients with HTG and hypercholesterolemia (HCH), CH level was significantly reduced (by 13.1%; pIII-V<0.05), mostly due to 33.1% decrease in low-density lipoprotein CH (pIII-V<0.001). Analysis of the association between ciprofibrate-induced TG decrease and oxidative parameters demonstrated greater numbers of the patients with inadequate hypotriglyceridemic effect among “fast” oxidative metabolisers than among “slow” ones. Among individuals with “fast” oxidation phenotype, ciprofibrate therapy had a moderate hypotriglyceridemic effect in 67% of subjects (p<0.05). Conclusion. In combined HTG and HCH, substantial hypotriglyceridemic activity of ciprofibrate was observed among patients with “slow” oxidation phenotype: TG concentration decreased by 35% (р<0.001). In “fast” oxidation phenotype group, TG level was reduced by 30% (р<0.05). Participants with both isolated and combined HTG demonstrated a substantial hypolipidemic effect of ciprofibrate in “slow” oxidation phenotype. гипертриглицеридемия ципрофибрат фенотип окисления симвастатин Diseases of the circulatory (Cardiovascular) system In Кардиоваскулярная терапия и профилактика «SILICEA-POLIGRAF» LLC, 2019 4(2005), 3, ч.II, Seite 69-74 (DE-627)1725534363 26190125 nnns volume:4 year:2005 number:3, ч.II pages:69-74 https://doaj.org/article/22fc39d529bb43c5be5d83422fbc8567 kostenfrei https://cardiovascular.elpub.ru/jour/article/view/954 kostenfrei https://doaj.org/toc/1728-8800 Journal toc kostenfrei https://doaj.org/toc/2619-0125 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2005 3, ч.II 69-74
allfieldsGer	(DE-627)DOAJ02410261X (DE-599)DOAJ22fc39d529bb43c5be5d83422fbc8567 DE-627 ger DE-627 rakwb rus RC666-701 G. S. Mal’ verfasserin aut Comparing efficacy of fibrates and statins in isolated and combined hypertriglyceridemia and various types of oxidative metabolism 2005 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim. To compare efficacy of simvastatin, a II generation statin, and ciprofibrate, a III generation fibrate, in various types of hyperlipidemia (HLP) and fibrate pharmacokinetic variants. Material and methods. The authors examined 156 males with primary HLP, aged 41-59. Inclusion criteria were: initial cholesterol (CH) >190 mg/dl; triglycerides (TG) >150 mg/dl; high-density lipoprotein CH >35 mg/dl. Clinical, biochemical, pharmacokinetic, and statistical methods were used. Results. Analysis of lipid-transport system in patients with isolated hypertriglyceridemia (HTG) during 8-week ciprofibrate therapy demonstrated decreases in TG (by 39.2%; pIII-V<0.05), and atherogenicity index, AI (by 28.6%; pIII-V<0.05). In patients with HTG and hypercholesterolemia (HCH), CH level was significantly reduced (by 13.1%; pIII-V<0.05), mostly due to 33.1% decrease in low-density lipoprotein CH (pIII-V<0.001). Analysis of the association between ciprofibrate-induced TG decrease and oxidative parameters demonstrated greater numbers of the patients with inadequate hypotriglyceridemic effect among “fast” oxidative metabolisers than among “slow” ones. Among individuals with “fast” oxidation phenotype, ciprofibrate therapy had a moderate hypotriglyceridemic effect in 67% of subjects (p<0.05). Conclusion. In combined HTG and HCH, substantial hypotriglyceridemic activity of ciprofibrate was observed among patients with “slow” oxidation phenotype: TG concentration decreased by 35% (р<0.001). In “fast” oxidation phenotype group, TG level was reduced by 30% (р<0.05). Participants with both isolated and combined HTG demonstrated a substantial hypolipidemic effect of ciprofibrate in “slow” oxidation phenotype. гипертриглицеридемия ципрофибрат фенотип окисления симвастатин Diseases of the circulatory (Cardiovascular) system In Кардиоваскулярная терапия и профилактика «SILICEA-POLIGRAF» LLC, 2019 4(2005), 3, ч.II, Seite 69-74 (DE-627)1725534363 26190125 nnns volume:4 year:2005 number:3, ч.II pages:69-74 https://doaj.org/article/22fc39d529bb43c5be5d83422fbc8567 kostenfrei https://cardiovascular.elpub.ru/jour/article/view/954 kostenfrei https://doaj.org/toc/1728-8800 Journal toc kostenfrei https://doaj.org/toc/2619-0125 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2005 3, ч.II 69-74
allfieldsSound	(DE-627)DOAJ02410261X (DE-599)DOAJ22fc39d529bb43c5be5d83422fbc8567 DE-627 ger DE-627 rakwb rus RC666-701 G. S. Mal’ verfasserin aut Comparing efficacy of fibrates and statins in isolated and combined hypertriglyceridemia and various types of oxidative metabolism 2005 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim. To compare efficacy of simvastatin, a II generation statin, and ciprofibrate, a III generation fibrate, in various types of hyperlipidemia (HLP) and fibrate pharmacokinetic variants. Material and methods. The authors examined 156 males with primary HLP, aged 41-59. Inclusion criteria were: initial cholesterol (CH) >190 mg/dl; triglycerides (TG) >150 mg/dl; high-density lipoprotein CH >35 mg/dl. Clinical, biochemical, pharmacokinetic, and statistical methods were used. Results. Analysis of lipid-transport system in patients with isolated hypertriglyceridemia (HTG) during 8-week ciprofibrate therapy demonstrated decreases in TG (by 39.2%; pIII-V<0.05), and atherogenicity index, AI (by 28.6%; pIII-V<0.05). In patients with HTG and hypercholesterolemia (HCH), CH level was significantly reduced (by 13.1%; pIII-V<0.05), mostly due to 33.1% decrease in low-density lipoprotein CH (pIII-V<0.001). Analysis of the association between ciprofibrate-induced TG decrease and oxidative parameters demonstrated greater numbers of the patients with inadequate hypotriglyceridemic effect among “fast” oxidative metabolisers than among “slow” ones. Among individuals with “fast” oxidation phenotype, ciprofibrate therapy had a moderate hypotriglyceridemic effect in 67% of subjects (p<0.05). Conclusion. In combined HTG and HCH, substantial hypotriglyceridemic activity of ciprofibrate was observed among patients with “slow” oxidation phenotype: TG concentration decreased by 35% (р<0.001). In “fast” oxidation phenotype group, TG level was reduced by 30% (р<0.05). Participants with both isolated and combined HTG demonstrated a substantial hypolipidemic effect of ciprofibrate in “slow” oxidation phenotype. гипертриглицеридемия ципрофибрат фенотип окисления симвастатин Diseases of the circulatory (Cardiovascular) system In Кардиоваскулярная терапия и профилактика «SILICEA-POLIGRAF» LLC, 2019 4(2005), 3, ч.II, Seite 69-74 (DE-627)1725534363 26190125 nnns volume:4 year:2005 number:3, ч.II pages:69-74 https://doaj.org/article/22fc39d529bb43c5be5d83422fbc8567 kostenfrei https://cardiovascular.elpub.ru/jour/article/view/954 kostenfrei https://doaj.org/toc/1728-8800 Journal toc kostenfrei https://doaj.org/toc/2619-0125 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2005 3, ч.II 69-74
language	Russian
source	In Кардиоваскулярная терапия и профилактика 4(2005), 3, ч.II, Seite 69-74 volume:4 year:2005 number:3, ч.II pages:69-74
sourceStr	In Кардиоваскулярная терапия и профилактика 4(2005), 3, ч.II, Seite 69-74 volume:4 year:2005 number:3, ч.II pages:69-74
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	гипертриглицеридемия ципрофибрат фенотип окисления симвастатин Diseases of the circulatory (Cardiovascular) system
isfreeaccess_bool	true
container_title	Кардиоваскулярная терапия и профилактика
authorswithroles_txt_mv	G. S. Mal’ @@aut@@
publishDateDaySort_date	2005-01-01T00:00:00Z
hierarchy_top_id	1725534363
id	DOAJ02410261X
language_de	russisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ02410261X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230410104803.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2005 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ02410261X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ22fc39d529bb43c5be5d83422fbc8567</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">G. S. Mal’</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Comparing efficacy of fibrates and statins in isolated and combined hypertriglyceridemia and various types of oxidative metabolism</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2005</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Aim. To compare efficacy of simvastatin, a II generation statin, and ciprofibrate, a III generation fibrate, in various types of hyperlipidemia (HLP) and fibrate pharmacokinetic variants. Material and methods. The authors examined 156 males with primary HLP, aged 41-59. Inclusion criteria were: initial cholesterol (CH) &gt;190 mg/dl; triglycerides (TG) &gt;150 mg/dl; high-density lipoprotein CH &gt;35 mg/dl. Clinical, biochemical, pharmacokinetic, and statistical methods were used. Results. Analysis of lipid-transport system in patients with isolated hypertriglyceridemia (HTG) during 8-week ciprofibrate therapy demonstrated decreases in TG (by 39.2%; pIII-V&lt;0.05), and atherogenicity index, AI (by 28.6%; pIII-V&lt;0.05). In patients with HTG and hypercholesterolemia (HCH), CH level was significantly reduced (by 13.1%; pIII-V&lt;0.05), mostly due to 33.1% decrease in low-density lipoprotein CH (pIII-V&lt;0.001). Analysis of the association between ciprofibrate-induced TG decrease and oxidative parameters demonstrated greater numbers of the patients with inadequate hypotriglyceridemic effect among “fast” oxidative metabolisers than among “slow” ones. Among individuals with “fast” oxidation phenotype, ciprofibrate therapy had a moderate hypotriglyceridemic effect in 67% of subjects (p&lt;0.05). Conclusion. In combined HTG and HCH, substantial hypotriglyceridemic activity of ciprofibrate was observed among patients with “slow” oxidation phenotype: TG concentration decreased by 35% (р&lt;0.001). In “fast” oxidation phenotype group, TG level was reduced by 30% (р&lt;0.05). Participants with both isolated and combined HTG demonstrated a substantial hypolipidemic effect of ciprofibrate in “slow” oxidation phenotype.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">гипертриглицеридемия</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ципрофибрат</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">фенотип окисления</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">симвастатин</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Кардиоваскулярная терапия и профилактика</subfield><subfield code="d">«SILICEA-POLIGRAF» LLC, 2019</subfield><subfield code="g">4(2005), 3, ч.II, Seite 69-74</subfield><subfield code="w">(DE-627)1725534363</subfield><subfield code="x">26190125</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:4</subfield><subfield code="g">year:2005</subfield><subfield code="g">number:3, ч.II</subfield><subfield code="g">pages:69-74</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/22fc39d529bb43c5be5d83422fbc8567</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://cardiovascular.elpub.ru/jour/article/view/954</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1728-8800</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2619-0125</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">4</subfield><subfield code="j">2005</subfield><subfield code="e">3, ч.II</subfield><subfield code="h">69-74</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	G. S. Mal’
spellingShingle	G. S. Mal’ misc RC666-701 misc гипертриглицеридемия misc ципрофибрат misc фенотип окисления misc симвастатин misc Diseases of the circulatory (Cardiovascular) system Comparing efficacy of fibrates and statins in isolated and combined hypertriglyceridemia and various types of oxidative metabolism
authorStr	G. S. Mal’
ppnlink_with_tag_str_mv	@@773@@(DE-627)1725534363
format	electronic Article
delete_txt_mv	keep
author_role	aut
collection	DOAJ
remote_str	true
callnumber-label	RC666-701
illustrated	Not Illustrated
issn	26190125
topic_title	RC666-701 Comparing efficacy of fibrates and statins in isolated and combined hypertriglyceridemia and various types of oxidative metabolism гипертриглицеридемия ципрофибрат фенотип окисления симвастатин
topic	misc RC666-701 misc гипертриглицеридемия misc ципрофибрат misc фенотип окисления misc симвастатин misc Diseases of the circulatory (Cardiovascular) system
topic_unstemmed	misc RC666-701 misc гипертриглицеридемия misc ципрофибрат misc фенотип окисления misc симвастатин misc Diseases of the circulatory (Cardiovascular) system
topic_browse	misc RC666-701 misc гипертриглицеридемия misc ципрофибрат misc фенотип окисления misc симвастатин misc Diseases of the circulatory (Cardiovascular) system
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Кардиоваскулярная терапия и профилактика
hierarchy_parent_id	1725534363
hierarchy_top_title	Кардиоваскулярная терапия и профилактика
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)1725534363
title	Comparing efficacy of fibrates and statins in isolated and combined hypertriglyceridemia and various types of oxidative metabolism
ctrlnum	(DE-627)DOAJ02410261X (DE-599)DOAJ22fc39d529bb43c5be5d83422fbc8567
title_full	Comparing efficacy of fibrates and statins in isolated and combined hypertriglyceridemia and various types of oxidative metabolism
author_sort	G. S. Mal’
journal	Кардиоваскулярная терапия и профилактика
journalStr	Кардиоваскулярная терапия и профилактика
callnumber-first-code	R
lang_code	rus
isOA_bool	true
recordtype	marc
publishDateSort	2005
contenttype_str_mv	txt
container_start_page	69
author_browse	G. S. Mal’
container_volume	4
class	RC666-701
format_se	Elektronische Aufsätze
author-letter	G. S. Mal’
title_sort	comparing efficacy of fibrates and statins in isolated and combined hypertriglyceridemia and various types of oxidative metabolism
callnumber	RC666-701
title_auth	Comparing efficacy of fibrates and statins in isolated and combined hypertriglyceridemia and various types of oxidative metabolism
abstract	Aim. To compare efficacy of simvastatin, a II generation statin, and ciprofibrate, a III generation fibrate, in various types of hyperlipidemia (HLP) and fibrate pharmacokinetic variants. Material and methods. The authors examined 156 males with primary HLP, aged 41-59. Inclusion criteria were: initial cholesterol (CH) >190 mg/dl; triglycerides (TG) >150 mg/dl; high-density lipoprotein CH >35 mg/dl. Clinical, biochemical, pharmacokinetic, and statistical methods were used. Results. Analysis of lipid-transport system in patients with isolated hypertriglyceridemia (HTG) during 8-week ciprofibrate therapy demonstrated decreases in TG (by 39.2%; pIII-V<0.05), and atherogenicity index, AI (by 28.6%; pIII-V<0.05). In patients with HTG and hypercholesterolemia (HCH), CH level was significantly reduced (by 13.1%; pIII-V<0.05), mostly due to 33.1% decrease in low-density lipoprotein CH (pIII-V<0.001). Analysis of the association between ciprofibrate-induced TG decrease and oxidative parameters demonstrated greater numbers of the patients with inadequate hypotriglyceridemic effect among “fast” oxidative metabolisers than among “slow” ones. Among individuals with “fast” oxidation phenotype, ciprofibrate therapy had a moderate hypotriglyceridemic effect in 67% of subjects (p<0.05). Conclusion. In combined HTG and HCH, substantial hypotriglyceridemic activity of ciprofibrate was observed among patients with “slow” oxidation phenotype: TG concentration decreased by 35% (р<0.001). In “fast” oxidation phenotype group, TG level was reduced by 30% (р<0.05). Participants with both isolated and combined HTG demonstrated a substantial hypolipidemic effect of ciprofibrate in “slow” oxidation phenotype.
abstractGer	Aim. To compare efficacy of simvastatin, a II generation statin, and ciprofibrate, a III generation fibrate, in various types of hyperlipidemia (HLP) and fibrate pharmacokinetic variants. Material and methods. The authors examined 156 males with primary HLP, aged 41-59. Inclusion criteria were: initial cholesterol (CH) >190 mg/dl; triglycerides (TG) >150 mg/dl; high-density lipoprotein CH >35 mg/dl. Clinical, biochemical, pharmacokinetic, and statistical methods were used. Results. Analysis of lipid-transport system in patients with isolated hypertriglyceridemia (HTG) during 8-week ciprofibrate therapy demonstrated decreases in TG (by 39.2%; pIII-V<0.05), and atherogenicity index, AI (by 28.6%; pIII-V<0.05). In patients with HTG and hypercholesterolemia (HCH), CH level was significantly reduced (by 13.1%; pIII-V<0.05), mostly due to 33.1% decrease in low-density lipoprotein CH (pIII-V<0.001). Analysis of the association between ciprofibrate-induced TG decrease and oxidative parameters demonstrated greater numbers of the patients with inadequate hypotriglyceridemic effect among “fast” oxidative metabolisers than among “slow” ones. Among individuals with “fast” oxidation phenotype, ciprofibrate therapy had a moderate hypotriglyceridemic effect in 67% of subjects (p<0.05). Conclusion. In combined HTG and HCH, substantial hypotriglyceridemic activity of ciprofibrate was observed among patients with “slow” oxidation phenotype: TG concentration decreased by 35% (р<0.001). In “fast” oxidation phenotype group, TG level was reduced by 30% (р<0.05). Participants with both isolated and combined HTG demonstrated a substantial hypolipidemic effect of ciprofibrate in “slow” oxidation phenotype.
abstract_unstemmed	Aim. To compare efficacy of simvastatin, a II generation statin, and ciprofibrate, a III generation fibrate, in various types of hyperlipidemia (HLP) and fibrate pharmacokinetic variants. Material and methods. The authors examined 156 males with primary HLP, aged 41-59. Inclusion criteria were: initial cholesterol (CH) >190 mg/dl; triglycerides (TG) >150 mg/dl; high-density lipoprotein CH >35 mg/dl. Clinical, biochemical, pharmacokinetic, and statistical methods were used. Results. Analysis of lipid-transport system in patients with isolated hypertriglyceridemia (HTG) during 8-week ciprofibrate therapy demonstrated decreases in TG (by 39.2%; pIII-V<0.05), and atherogenicity index, AI (by 28.6%; pIII-V<0.05). In patients with HTG and hypercholesterolemia (HCH), CH level was significantly reduced (by 13.1%; pIII-V<0.05), mostly due to 33.1% decrease in low-density lipoprotein CH (pIII-V<0.001). Analysis of the association between ciprofibrate-induced TG decrease and oxidative parameters demonstrated greater numbers of the patients with inadequate hypotriglyceridemic effect among “fast” oxidative metabolisers than among “slow” ones. Among individuals with “fast” oxidation phenotype, ciprofibrate therapy had a moderate hypotriglyceridemic effect in 67% of subjects (p<0.05). Conclusion. In combined HTG and HCH, substantial hypotriglyceridemic activity of ciprofibrate was observed among patients with “slow” oxidation phenotype: TG concentration decreased by 35% (р<0.001). In “fast” oxidation phenotype group, TG level was reduced by 30% (р<0.05). Participants with both isolated and combined HTG demonstrated a substantial hypolipidemic effect of ciprofibrate in “slow” oxidation phenotype.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	3, ч.II
title_short	Comparing efficacy of fibrates and statins in isolated and combined hypertriglyceridemia and various types of oxidative metabolism
url	https://doaj.org/article/22fc39d529bb43c5be5d83422fbc8567 https://cardiovascular.elpub.ru/jour/article/view/954 https://doaj.org/toc/1728-8800 https://doaj.org/toc/2619-0125
remote_bool	true
ppnlink	1725534363
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
callnumber-a	RC666-701
up_date	2024-07-03T21:12:43.685Z
_version_	1803593883255308288
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ02410261X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230410104803.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2005 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ02410261X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ22fc39d529bb43c5be5d83422fbc8567</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">G. S. Mal’</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Comparing efficacy of fibrates and statins in isolated and combined hypertriglyceridemia and various types of oxidative metabolism</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2005</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Aim. To compare efficacy of simvastatin, a II generation statin, and ciprofibrate, a III generation fibrate, in various types of hyperlipidemia (HLP) and fibrate pharmacokinetic variants. Material and methods. The authors examined 156 males with primary HLP, aged 41-59. Inclusion criteria were: initial cholesterol (CH) &gt;190 mg/dl; triglycerides (TG) &gt;150 mg/dl; high-density lipoprotein CH &gt;35 mg/dl. Clinical, biochemical, pharmacokinetic, and statistical methods were used. Results. Analysis of lipid-transport system in patients with isolated hypertriglyceridemia (HTG) during 8-week ciprofibrate therapy demonstrated decreases in TG (by 39.2%; pIII-V&lt;0.05), and atherogenicity index, AI (by 28.6%; pIII-V&lt;0.05). In patients with HTG and hypercholesterolemia (HCH), CH level was significantly reduced (by 13.1%; pIII-V&lt;0.05), mostly due to 33.1% decrease in low-density lipoprotein CH (pIII-V&lt;0.001). Analysis of the association between ciprofibrate-induced TG decrease and oxidative parameters demonstrated greater numbers of the patients with inadequate hypotriglyceridemic effect among “fast” oxidative metabolisers than among “slow” ones. Among individuals with “fast” oxidation phenotype, ciprofibrate therapy had a moderate hypotriglyceridemic effect in 67% of subjects (p&lt;0.05). Conclusion. In combined HTG and HCH, substantial hypotriglyceridemic activity of ciprofibrate was observed among patients with “slow” oxidation phenotype: TG concentration decreased by 35% (р&lt;0.001). In “fast” oxidation phenotype group, TG level was reduced by 30% (р&lt;0.05). Participants with both isolated and combined HTG demonstrated a substantial hypolipidemic effect of ciprofibrate in “slow” oxidation phenotype.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">гипертриглицеридемия</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ципрофибрат</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">фенотип окисления</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">симвастатин</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Кардиоваскулярная терапия и профилактика</subfield><subfield code="d">«SILICEA-POLIGRAF» LLC, 2019</subfield><subfield code="g">4(2005), 3, ч.II, Seite 69-74</subfield><subfield code="w">(DE-627)1725534363</subfield><subfield code="x">26190125</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:4</subfield><subfield code="g">year:2005</subfield><subfield code="g">number:3, ч.II</subfield><subfield code="g">pages:69-74</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/22fc39d529bb43c5be5d83422fbc8567</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://cardiovascular.elpub.ru/jour/article/view/954</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1728-8800</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2619-0125</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">4</subfield><subfield code="j">2005</subfield><subfield code="e">3, ч.II</subfield><subfield code="h">69-74</subfield></datafield></record></collection>
score	7.4027834

Nicht das Richtige dabei?

Schreiben Sie uns!

Comparing efficacy of fibrates and statins in isolated and combined hypertriglyceridemia and various types of oxidative metabolism

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?